KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Operations: 2018-2024

Historic Cash from Operations for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $2.8 billion.

  • Royalty Pharma's Cash from Operations fell 0.14% to $702.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 14.07%. This contributed to the annual value of $2.8 billion for FY2024, which is 7.32% down from last year.
  • As of FY2024, Royalty Pharma's Cash from Operations stood at $2.8 billion, which was down 7.32% from $3.0 billion recorded in FY2023.
  • Royalty Pharma's Cash from Operations' 5-year high stood at $3.0 billion during FY2023, with a 5-year trough of $2.0 billion in FY2021.
  • For the 3-year period, Royalty Pharma's Cash from Operations averaged around $2.6 billion, with its median value being $2.8 billion (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 39.36% in 2023, then decreased by 7.32% in 2024.
  • Over the past 5 years, Royalty Pharma's Cash from Operations (Yearly) stood at $2.0 billion in 2020, then dropped by 0.84% to $2.0 billion in 2021, then grew by 6.27% to $2.1 billion in 2022, then skyrocketed by 39.36% to $3.0 billion in 2023, then declined by 7.32% to $2.8 billion in 2024.